

## FOI 21/876 - GATES FUNDING RECEIVED 2010-2021

Project Name	Relevant Years (2010-2021)	Relevant Funding	Relevant Funding	Project Description
		Amount 2010-2021 USD (\$)	Amount 2010-2021 GBP (£)	
Grand Challenges - GATES	3.00		248,754	Development of mucosal applied vaccines to protect against HIV, in consortium with St George's Hospital. NIBSC evaluated the vaccines in NHP models.
GHAVE GHRC	2.00	80,949		evaluation of candidate HIV vaccines in the Non Human Primate Model in collaboration with Imperial College, London.
Collaboration for AIDS vaccine discovery programme	2.00	830,936		Collaboration for the development of cold chain technology to facilitate shipping of biologicals and exchange of HIV research materials between the NIBSC Centre for AIDS Reagents Repository and the CAVD HIV Cryorepository.
High through put analysis of avian influenza variants	4.50	944,031		Project goal to obtain comprehensive knowledge of mammalian adapting changes in influenza viruses to predict the pandemic potential of newly emerging strains. NIBSC role was the antigenic characterisation of Hemagglutinin mutants
Genetically Stable OPV-2	9.50		1,197,875	Design and generation of genetically stable live attenuated polio vaccine candidates specifically new OPV-2 vaccine candidates as part of a consortium
Typhoid Conjugate Vaccine - GATES	3.00	282,213		Development and validation of serological assays for anti Vi Capsular polysaccharide antibodies. Improvement of standardisation of typhoid conjugate vaccines and prequalification of a conjugate vaccine
Novel Oral Polio Vaccine product development	0.30		180,769	Production of reference materials to support quality control of sIPV vaccines for Poliovirus
GBS Consortium	5.00	304,064		Establishment of a Group B Strep consortium to develop standard reagents for use with standardised assays (immunogenicity and functional antibody assays) to facilitate reproducibility across laboratories.
nOPV CRO Training	1.00	430,873		Provision of training and expertise to support Contract Research Organisation to develop clinical assays for New Oral Polio Vaccine
HuAb against Pertussis	3.00		200,000	Assessment of human anti pertussis monoclonal antibodies from KyMab mouse model and use of neutralising antibodies as a bordetella Pertussis prophylaxis.
sIPV-PATH	4.00		210,145	standardisation of Assays for Sabin inactivated Polio Virus
GATES Imperial Poliovirus Environmental Surveillance	3.50	254,451		Development of analytic and sequencing tools for the Polio virus to define and identify Poliovirus in the environment and in clinical samples.
nOPV CRO Training-year 2	3.75	247,993		Provision of training and expertise to support Contract Research Organisation to develop clinical assays for New Oral Polio Vaccine
Shigella Antibody Inter-site Collaborative Study	2.50	48,647		Collaboration for the harmonisation of current Shigella OAg ELISAs and the potential source of a new Shigella standard
HA Stalk Based Antibody std	1.50	375,710		Production of a standard for Antibody to (hemagglutinin) HA stem domain (influenza)
WHO GBS Standard	1.50	240,565		International Group B Streptococcus (GBS) polysaccharides and human reference serum standards
Shigella WHO IS	1.50	427,787		To generate the first international standard serum for the quantification of Shigella antibodies in response to vaccination with candidate Shigella vaccines in development
Using Physiologically based Pharmacokinetic Modelling & Simulations 1	2.00	360,300		Using Physiologically based Pharmacokinetic Modelling & Simulations to inform Medicines Benefit/risk and dosing decisions during Pregnancy
Redefining development paradigm for long term contraceptives	1.00	167,585		Redefining development paradigm for long term contraceptives
Pharmacovigilance capacity in Low & Middle income countries	3.50	1,308,530		Pharmacovigilance capacity in Low & Middle income countries
		<b>6,304,634</b>	<b>2,037,543</b>	